Armata Pharmaceuticals (ARMP) Corporate presentation summary

Phage platform and strategy

• Phage therapy is presented as a pathogen-specific alternative or adjunct to antibiotics, with activity independent of antibiotic resistance and less disruption to the normal microbiome.

• Three randomized controlled Phase 2 trials have been completed across AP-SA02 and AP-PA02 programs; strategy targets rapid regulatory progress alongside expansion into larger indications.

• Platform capabilities span phage and pathogen libraries, computational biology, preclinical development, analytical sciences, CMC and clinical development.

• Potential platform extensions include additional indications for Staphylococcus aureus and Pseudomonas aeruginosa, plus pathogens such as Klebsiella pneumoniae and Acinetobacter baumannii.

AP-SA02 lead program

• AP-SA02 is an IV phage cocktail for complicated S. aureus bacteremia; it targets ~95% of S. aureus clinical isolates and is being developed with best-available therapy antibiotics.

• In Phase 2a diSArm, clinical response improved significantly versus standard of care; FDA agreed the Phase 2 efficacy data support starting a Phase 3 trial.

• Phase 2a safety data showed one study-drug-related TEAE in the AP-SA02 arm and no treatment-related SAEs; the presentation characterized the treatment as well tolerated.

• Proposed Phase 3 design: N=450, with 300 receiving a full 7-day treatment course; 95% power to detect a 15% difference at 0.05 alpha.

• QIDP designation was granted in 1Q26; Fast Track and Breakthrough Therapy designations were also cited.

AP-PA02 and other pipeline programs

• AP-PA02 completed Phase 2 studies in chronic P. aeruginosa respiratory infections in NCFB and cystic fibrosis; the program is positioned for a pivotal study.

• Tailwind enrolled 48 subjects across 23 U.S. sites; treatment was nebulized twice daily for 10 days, as monotherapy or with inhaled antibiotics.

• Preliminary post hoc ITT analysis found significant reductions in P. aeruginosa density versus baseline on Days 10, 11, 17 and 24 in treated subjects, but not placebo; data remained subject to review and QC.

• AP-PA03 is in IND-enabling work for acute P. aeruginosa respiratory infections, including ventilator-associated pneumonia; AP-SA02 also has an IND-cleared prosthetic joint infection program.